What is the appropriate dosing, contraindications, and monitoring for Caplyta (lumateperone) in adults with schizophrenia or bipolar depression?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: September 16, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Ask Question

Caplyta (Lumateperone) for Schizophrenia and Bipolar Depression

Caplyta (lumateperone) 42 mg once daily is the recommended dose for treating schizophrenia and bipolar depression in adults, taken with or without food, and requires no dose titration. 1

Approved Indications

Caplyta is FDA-approved for:

  • Schizophrenia in adults 1
  • Depressive episodes associated with bipolar I or II disorder (bipolar depression) as monotherapy or adjunctive therapy with lithium or valproate 1

Dosing

Standard Dosing

  • 42 mg once daily (oral capsule)
  • No titration required
  • Can be taken with or without food 1

Dose Adjustments

Hepatic Impairment:

  • Moderate or severe hepatic impairment (Child-Pugh B or C): 21 mg once daily 1

Drug Interactions:

  • Strong CYP3A4 inhibitors (e.g., ketoconazole, clarithromycin): 10.5 mg once daily 1
  • Moderate CYP3A4 inhibitors (e.g., diltiazem, fluconazole): 21 mg once daily 1
  • CYP3A4 inducers (e.g., rifampin, carbamazepine): Avoid concomitant use 1

Contraindications

Absolute contraindication: Known hypersensitivity to lumateperone or any component of Caplyta, including reactions such as pruritus, rash (allergic dermatitis, papular rash, generalized rash), or urticaria 1

Critical Warnings (Black Box)

  1. Increased mortality in elderly patients with dementia-related psychosis - Caplyta is NOT approved for this population 1

  2. Suicidal thoughts and behaviors - Antidepressants increase risk in pediatric and young adult patients. Close monitoring required for clinical worsening and emergence of suicidal thoughts. Caplyta is not approved for pediatric use 1

Monitoring Requirements

Baseline Assessment

  • Complete blood count (CBC) if pre-existing low WBC or history of leukopenia/neutropenia 1
  • Blood pressure and heart rate 1
  • Weight and metabolic parameters (glucose, lipids) 1
  • Liver function tests 1

Ongoing Monitoring

Metabolic Parameters:

  • Monitor for hyperglycemia/diabetes mellitus, dyslipidemia, and weight gain 1

Hematologic:

  • Perform CBC monitoring in patients with pre-existing low WBC or history of drug-induced leukopenia/neutropenia
  • Consider discontinuation if clinically significant WBC decline occurs without other causative factors 1

Cardiovascular:

  • Monitor blood pressure and heart rate, especially in patients with cardiovascular/cerebrovascular disease or risk of dehydration 1

Neurological:

  • Assess for extrapyramidal symptoms (EPS) using standardized scales
  • Monitor for tardive dyskinesia - discontinue if clinically appropriate 1
  • Watch for neuroleptic malignant syndrome (rare but serious) 1

Psychiatric:

  • Monitor for suicidal thoughts/behaviors, particularly when initiating treatment 1
  • Assess for mania/hypomania switches in bipolar patients 1

Safety Profile

Common Adverse Reactions (≥5% and >2× placebo)

Schizophrenia:

  • Somnolence/sedation (24% vs 10% placebo)
  • Dry mouth (6% vs 2% placebo) 1

Bipolar Depression (Monotherapy):

  • Somnolence/sedation (13% vs 3% placebo)
  • Dizziness (8% vs 4% placebo)
  • Nausea (8% vs 3% placebo)
  • Dry mouth (5% vs 1% placebo) 1

Bipolar Depression (Adjunctive):

  • Somnolence/sedation (13% vs 3% placebo)
  • Dizziness (11% vs 2% placebo)
  • Nausea (9% vs 4% placebo)
  • Dry mouth (5% vs 1% placebo) 1

Key Safety Advantages

  • Minimal EPS risk - rates similar to placebo 1, 2, 3
  • No clinically significant metabolic changes - minimal weight gain, lipid changes, or glucose abnormalities 1, 2, 3
  • No prolactin elevation (except rare cases in adjunctive therapy) 1, 3
  • Low akathisia rates 1, 2

Efficacy Data

Schizophrenia: 42 mg demonstrated statistically significant improvement in PANSS total score (LSMD -4.2, p=0.02, ES -0.3) and CGI-S (LSMD -0.3, p=0.003, ES -0.4) at day 28 2

Bipolar Depression (Monotherapy): 42 mg showed significant improvement in MADRS (LSMD -4.6, ES -0.56) and CGI-BP-S (LSMD -0.9, ES -0.46) at day 43 3

Bipolar Depression (Adjunctive): 42 mg demonstrated significant improvement in MADRS (LSMD -2.4, p=0.02) and CGI-BP-S depression subscore (LSMD -0.3, p=0.01) at day 43 4

Mixed Features: Effective in both MDD and bipolar depression with mixed features, with significant MADRS improvement (LSMD -5.7, ES -0.64, p<0.0001) 5

Special Populations

Pregnancy: May cause extrapyramidal and/or withdrawal symptoms in neonates with third trimester exposure 1

Pediatric: Safety and effectiveness not established 1

Elderly: Use caution due to increased risk of cerebrovascular events and falls 1

Clinical Pearls

  • No titration needed - start at target dose of 42 mg, unlike many other antipsychotics
  • Favorable metabolic profile - particularly advantageous for patients at cardiometabolic risk
  • Low EPS burden - suitable for patients sensitive to motor side effects
  • Evening dosing recommended due to somnolence/sedation profile
  • Effective across bipolar subtypes - works in both bipolar I and II depression 3, 6

References

Related Questions

Is Caplyta (lumateperone) indicated for bipolar I disorder or bipolar II disorder?
Is caplyta (lumateperone) appropriate for a patient with bipolar disorder presenting with alternating manic episodes (elevated mood, racing thoughts, impulsivity, hypersexuality) and depressive episodes (anhedonia, fatigue, passive suicidal ideation) with psychotic symptoms, who wishes to avoid a stigmatizing diagnosis?
In a female patient who experienced intrusive thoughts with lamotrigine and renal impairment with lithium, what is the recommended use of Caplyta (lumateperone) for depression, including dosing and appropriate adjunct antidepressant therapy?
Is this medication regimen (lamotrigine 150 mg, amitriptyline 25 mg, quetiapine 400 mg, and lumateperone (Caplyta) 42 mg) appropriate for a patient with bipolar I disorder, generalized anxiety disorder, and insomnia?
What are the recommended starting dose, titration schedule, monitoring parameters, contraindications, and switching options for Caplyta (lumateperone) in adults with schizophrenia or bipolar I depression?
For an adult with a serum magnesium of 0.8 mmol/L and normal calcium and potassium levels, can oral magnesium replacement be used, and what dose and dosing schedule should be employed?
In a 50-year-old man with normal total testosterone and SHBG, does a slightly elevated free testosterone (~9.5 pg/mL) and bioavailable testosterone (~232 ng/dL) require any treatment?
What is the likely cause of early‑morning sweats and transient hot flashes in a 56‑year‑old male with acute myeloid leukemia who completed intensive 7+3 chemotherapy, had a normal complete blood count and bone marrow aspirate indicating remission on day 23, was discharged on day 24, and now on day 26 presents with these symptoms?
Can the valsartan/hydrochlorothiazide 120 mg/12.5 mg tablet be split in half?
Is there a lower dose of the valsartan/hydrochlorothiazide (HCTZ) combination available?
What is the recommended diagnostic and treatment approach for streptococcal septic arthritis?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.